Eli Lilly's Foundayo Forges New Path with Amazon as Political Headwinds Bite

Eli Lilly launches oral weight-loss drug Foundayo via Amazon Pharmacy but faces investor anxiety over price concessions and tariffs, with Q1 earnings in focus.

Eli Lilly's stock is caught in a tug-of-war between a groundbreaking commercial strategy and mounting political pressures. While the pharmaceutical giant has launched its oral weight-loss drug Foundayo with a powerful new distribution partner, its shares have fallen roughly 13% since the start of the year, recently trading around 818.00 EUR. This disconnect highlights investor anxiety over price concessions and tariffs, even as the company executes an aggressive market entry.

The centerpiece of Lilly's offensive is a strategic partnership with Amazon Pharmacy. To avoid the supply constraints that have plagued rival injectable treatments, the company is leveraging Amazon's logistics network for same-day delivery of Foundayo. The service launches immediately in nearly 3,000 cities, with plans to expand to 4,500 by year-end. In a novel move for traditional pharmacy, Amazon will also install dispensing kiosks in select One Medical clinics, allowing patients to pick up their prescription immediately after a doctor's visit.

This logistics push supports the launch of Foundayo, an oral GLP-1 medication approved ahead of schedule on April 10. The pill targets patients averse to injections and positions Lilly in direct competition with Novo Nordisk's oral version of Wegovy. According to analyst Andy Hsieh of William Blair, Foundayo holds a key advantage: it can be taken without food or fluid restrictions, potentially boosting patient adoption. Lilly is also pursuing an aggressive pricing strategy, with costs for insured patients starting at $25 per month.

However, political developments are casting a shadow over these operational strides. To avert threatened pharmaceutical tariffs, Eli Lilly has struck a deal with the Trump administration. The company is granting price discounts for certain treatments for Medicare and Medicaid patients and offering direct rebates to consumers. In exchange, it receives a three-year exemption from tariffs. These concessions are expected to pressure near-term revenues, even as sales volumes rise. With the stock trading at a forward price-to-earnings ratio above 27—nearly double the industry average—investors are particularly sensitive to such margin risks.

The competitive landscape is intensifying. Novo Nordisk has countered with cross-study data purporting to show superior weight loss for its own drug. Undeterred, Eli Lilly is securing additional channels; Weight Watchers began offering Foundayo through its Med-Plus program yesterday. Analysts at Bank of America project the drug could generate $2 billion in revenue this year alone. To prepare for high demand, Lilly has already built up $1.5 billion worth of Foundayo inventory.

All eyes now turn to the company's first-quarter earnings report on April 30. Wall Street expectations are steep, with earnings per share forecast to surge 126% year-over-year to $7.55. The primary focus will be the first sales figures for Foundayo. Revenue hitting or surpassing the $500 million mark for the quarter would signal unexpectedly rapid growth for the oral GLP-1 market. Simultaneously, management will likely need to address its full-year revenue guidance of $80 to $83 billion in light of recent political and commercial developments. The results will serve as the first major test of whether Foundayo's launch momentum can outweigh the sector's political headwinds.